Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension
| العنوان: | Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension |
|---|---|
| المؤلفون: | Biff F. Palmer, Rita Samuel, Dion H. Zappe, Das Purkayastha, David A. Calhoun, Kenneth Jamerson |
| المصدر: | Journal of Human Hypertension |
| بيانات النشر: | Springer Science and Business Media LLC, 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Urology, Tetrazoles, Pharmacology, valsartan, valsartan/hydrochlorothiazide, Hydrochlorothiazide, Internal Medicine, Humans, Medicine, initial combination therapy, Antihypertensive Agents, Thiazide, Aged, business.industry, Valine, Middle Aged, Angiotensin II, Treatment Outcome, Blood pressure, Tolerability, Valsartan, Hypertension, Valsartan/hydrochlorothiazide, Original Article, Drug Therapy, Combination, Female, Diuretic, business, medicine.drug |
| الوصف: | This prospective, 6-week, multicenter, double-blind study examined the benefits of initiating treatment with combination valsartan/hydrochlorothiazide (HCTZ) compared with initial valsartan monotherapy for 648 patients with stage-1 or stage-2 hypertension (age=52.6+/-10 years; 54% male; baseline blood pressure (BP)=161/98 mm Hg, 32% stage 1). Patients were randomized to valsartan 80 mg (V-low), valsartan 160 mg (V-high) or valsartan/HCTZ 160/12.5 mg (V/HCTZ), and electively titrated after weeks 2 and 4 to the next dosage level (maximum dose valsartan/HCTZ 160/25 mg) if BP remained140/90 mm Hg. At end of the study, patients initiated with V/HCTZ required less titration steps compared with the initial valsartan monotherapy groups (63 vs 86% required titration by study end, respectively) and reached the target BP goal of140/90 mm Hg in a shorter period of time (2.8 weeks) (P0.0001) vs V-low (4.3 weeks) and V-high (3.9 weeks). Initial combination therapy was also associated with higher BP control rates and greater reductions in both systolic and diastolic BP from baseline (63%, -27.7+/-13/-15.1+/-8 mm Hg) compared with V-low (46%, -21.2+/-13/-11.4+/-8 mm Hg, P0.0001) or V-high (51%, -24.0+/-13/-12.0+/-10 mm Hg, P0.01). Overall and drug-related AEs were mild to moderate and were similar between V/HCTZ (53.1 and 14.1%, respectively) and the two monotherapy groups, V-low (50.5 and 13.8%) and V-high (50.7 and 11.8%). In conclusion, initiating therapy with a combination of valsartan and low-dose HCTZ results in early, improved BP efficacy with similar tolerability as compared with starting treatment with a low or higher dose of valsartan for patients with stage-1 and stage-2 hypertension. |
| تدمد: | 1476-5527 0950-9240 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e96ffd2e92f9a9c8461a4ea0dfe06f9Test https://doi.org/10.1038/jhh.2009.90Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....0e96ffd2e92f9a9c8461a4ea0dfe06f9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765527 09509240 |
|---|